地西他滨对比羟基脲治疗晚期增殖型慢性粒单核细胞白血病:EMSCO网络随机III期试验结果
在170例新诊断晚期增殖型慢性粒单核细胞白血病(CMML)患者中,1:1随机接受地西他滨(DAC)或羟基脲(HY)治疗。中位随访17.5个月,中位无事件生存期(EFS)DAC组12.1个月 vs HY组10.3个月(HR 0.83,95%CI 0.59-1.16,P=0.27),无显著差异;DAC组缓解率63% vs HY组35%(P=0.0004),但中位总生存期无显著差异。
要点
- DAC组中位EFS 12.1个月 vs HY组10.3个月(HR 0.83,95%CI 0.59-1.16,P=0.27),无显著差异。
- DAC组缓解率63%(53例) vs HY组35%(30例),P=0.0004。
- DAC较HY显著降低CMML进展或转化为急性粒单核细胞白血病的风险(cause-specific HR 0.62,95%CI 0.41-0.94,P=0.005),但以无进展或转化死亡为代价(cause-specific HR 1.55,95%CI 0.82-2.9,P=0.04)。
核心结论
- 与羟基脲相比,一线地西他滨治疗未改善晚期增殖型CMML患者的无事件生存期(EFS)。
研究设计与样本
- 随机III期试验,新诊断晚期增殖型CMML患者1:1随机接受静脉地西他滨(20 mg/m2/d,第1-5天)或羟基脲(1-4 g/d),28天为一周期。
- 共170例患者接受治疗,DAC组84例,HY组86例。
主要发现
- 中位年龄DAC组72岁、HY组74岁;中位白细胞计数DAC组32.5×10^9/L、HY组31.2×10^9/L。
- DAC组33%、HY组31%的患者为CMML-2;中位治疗周期数DAC组5个、HY组6个。
- 中位随访17.5个月,中位EFS DAC组12.1个月 vs HY组10.3个月(HR 0.83,95%CI 0.59-1.16,P=0.27)。
- 缓解率DAC组63%(53例) vs HY组35%(30例),P=0.0004;中位缓解持续时间DAC组16.3个月 vs HY组17.4个月(P=0.90)。
- 中位总生存期DAC组18.4个月 vs HY组21.9个月(P=0.67);DAC较HY显著降低CMML进展或转化为急性粒单核细胞白血病的风险(cause-specific HR 0.62,95%CI 0.41-0.94,P=0.005),但以无进展或转化死亡为代价(cause-specific HR 1.55,95%CI 0.82-2.9,P=0.04)。
关键数值与推荐
- 治疗效应与原始细胞数、血小板计数、贫血、CMML预后评分系统、Groupe Francophone des Myelodysplasies或CMML预后评分系统-分子风险之间无显著交互作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hydroxyurea (HY) is a reference treatment of advanced myeloproliferative neoplasms. We conducted a randomized phase III trial comparing decitabine (DAC) and HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML). PATIENTS AND METHODS: Newly diagnosed myeloproliferative CMML patients with advanced disease were randomly assigned 1:1 to intravenous DAC (20 mg/m2/d days 1-5) or HY (1-4 g/d) in 28-day cycles. The primary end point was event-free survival (EFS), events being death and acute myelomonocytic leukemia (AML) transformation or progression. RESULTS: One-hundred seventy patients received DAC (n = 84) or HY (n = 86). Median age was 72 and 74 years, and median WBC count 32.5 × 109/L and 31.2 × 109/L in the DAC and HY arms, respectively. Thirty-three percent of DAC and 31% of HY patients had CMML-2. Patients received a median of five DAC and six HY cycles. With a median follow-up of 17.5 months, median EFS was 12.1 months in the DAC arm and 10.3 months in the HY arm (hazard ratio [HR], 0.83; 95% CI, 0.59 to 1.16; P = .27). There was no significant interaction between treatment effect and blast or platelet count, anemia, CMML Prognostic Scoring System, Groupe Francophone des Myelodysplasies, or CMML Prognostic Scoring System-mol risk. Fifty-three (63%) DAC patients achieved a response compared with 30 (35%) HY patients (P = .0004). Median duration of response was similar in both arms (DAC, 16.3 months; HY, 17.4 months; P = .90). Median overall survival was 18.4 months in the DAC arm and 21.9 months in the HY arm (P = .67). Compared with HY, DAC significantly reduced the risk of CMML progression or transformation to acute myelomonocytic leukemia (cause-specific HR, 0.62; 95% CI, 0.41 to 0.94; P = .005) at the expense of death without progression or transformation (cause-specific HR, 1.55; 95% CI, 0.82 to 2.9; P = .04). CONCLUSION: Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML (ClinicalTrials.gov identifier: NCT02214407).
引用
- Itzykson R, Santini V, Thepot S, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2022. PMID: 36455187. doi:10.1200/JCO.22.00437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。